Vaxxinity (OTCMKTS:VAXX – Get Free Report) is expected to be announcing its resultson Wednesday, November 11th. Analysts expect the company to post earnings of ($0.12) per share for the quarter.
Vaxxinity Trading Up 14,900.0%
Vaxxinity stock opened at $0.01 on Wednesday. Vaxxinity has a 12 month low of $0.00 and a 12 month high of $0.20. The stock’s 50 day simple moving average is $0.01 and its two-hundred day simple moving average is $0.01. The firm has a market cap of $1.90 million, a PE ratio of -0.08 and a beta of -71.72.
About Vaxxinity
Vaxxinity Inc is a biotechnology company focused on developing vaccines and immunotherapies for chronic diseases, including neurodegenerative conditions. The company’s approach is designed to stimulate the body’s immune system to target disease-related proteins or pathways, with the goal of addressing underlying disease biology rather than treating symptoms alone.
Vaxxinity’s research and development pipeline has included UB-311, an investigational vaccine targeting amyloid beta for Alzheimer’s disease, and UB-312, an investigational vaccine designed to target abnormal alpha-synuclein associated with Parkinson’s disease and other synucleinopathies.
See Also
- Five stocks we like better than Vaxxinity
- Meta’s $100 Billion AI Financing Plan Has a Catch for Existing Shareholders
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
Receive News & Ratings for Vaxxinity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxxinity and related companies with MarketBeat.com's FREE daily email newsletter.
